INM vs. IBIO, FLGC, SYBX, MRKR, NXTC, AYTU, CLDI, BCTX, CLRB, and BGXX
Should you be buying InMed Pharmaceuticals stock or one of its competitors? The main competitors of InMed Pharmaceuticals include iBio (IBIO), Flora Growth (FLGC), Synlogic (SYBX), Marker Therapeutics (MRKR), NextCure (NXTC), Aytu BioPharma (AYTU), Calidi Biotherapeutics (CLDI), BriaCell Therapeutics (BCTX), Cellectar Biosciences (CLRB), and Bright Green (BGXX). These companies are all part of the "pharmaceutical products" industry.
InMed Pharmaceuticals vs.
InMed Pharmaceuticals (NASDAQ:INM) and iBio (NYSE:IBIO) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, community ranking, analyst recommendations, earnings, risk, profitability and media sentiment.
iBio has a net margin of 0.00% compared to InMed Pharmaceuticals' net margin of -163.75%. iBio's return on equity of -73.15% beat InMed Pharmaceuticals' return on equity.
In the previous week, InMed Pharmaceuticals' average media sentiment score of 0.00 equaled iBio'saverage media sentiment score.
InMed Pharmaceuticals has higher revenue and earnings than iBio.
InMed Pharmaceuticals has a beta of 0.21, meaning that its stock price is 79% less volatile than the S&P 500. Comparatively, iBio has a beta of 1.19, meaning that its stock price is 19% more volatile than the S&P 500.
InMed Pharmaceuticals received 4 more outperform votes than iBio when rated by MarketBeat users. Likewise, 47.06% of users gave InMed Pharmaceuticals an outperform vote while only 44.44% of users gave iBio an outperform vote.
20.1% of InMed Pharmaceuticals shares are owned by institutional investors. Comparatively, 7.9% of iBio shares are owned by institutional investors. 1.9% of InMed Pharmaceuticals shares are owned by company insiders. Comparatively, 0.6% of iBio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
iBio has a consensus price target of $4.30, indicating a potential upside of 465.79%. Given iBio's stronger consensus rating and higher probable upside, analysts clearly believe iBio is more favorable than InMed Pharmaceuticals.
Summary
iBio beats InMed Pharmaceuticals on 8 of the 14 factors compared between the two stocks.
Get InMed Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for INM and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
InMed Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:INM) was last updated on 5/22/2025 by MarketBeat.com Staff
Buy INM Stock Free INM Stock Alerts